Hexarelin lab monitoring
Which blood work to run before, during and after a hexarelin cycle, and what the research can and can't tell you about the results. Hexarelin is an older growth hormone-releasing peptide. Unlike ipamorelin, each injection briefly raises cortisol and prolactin as well as GH, and the GH response fades with repeated use. So this panel adds morning cortisol and prolactin to the usual GH-axis markers.
When to test
1. Baseline (before you start)
| Marker | Why test it | Standard range |
|---|---|---|
| IGF-1 Insulin-like growth factor 1 | Your reference point. Over 16 weeks of twice-daily injections, IGF-1 did not change significantly (PMID 9589671), so don't expect it to move. | Depends on age and sex. Labcorp adult examples: ages 21-25, men 109-353 and women 101-347; ages 41-45, men 84-270 and women 74-239; ages 56-60, men 68-247 and women 60-207 ng/mL Source: Labcorp test 010363 |
| Fasting glucose Fasting plasma glucose | Growth hormone works against insulin (PMID 29025199), so you want your starting glucose before you push the GH axis. Fast for at least 8 hours before the draw. | Normal under 100; prediabetes 100-125; diabetes 126 or higher mg/dL Source: American Diabetes Association |
| HbA1c Hemoglobin A1c | A one-off screen for existing blood-sugar problems. It reflects roughly the last 3 months, so fasting glucose is the marker to repeat during a cycle. | Normal under 5.7%; prediabetes 5.7-6.4%; diabetes 6.5% or higher Source: American Diabetes Association |
| CBC Complete blood count | A standard safety baseline before any injectable peptide, so you have your own reference point if you feel unwell during the cycle. | WBC 4.0-10 k/mcL; hemoglobin 13-17 g/dL men, 11.5-15.5 g/dL women; platelets 150-400 k/mcL Source: Cleveland Clinic |
| Cortisol Serum cortisol, morning | Draw at about 8 a.m., before your morning dose. Each dose causes a short cortisol rise (PMID 9253314); your pre-dose baseline is what tells a lasting change apart from that spike. | Morning (AM) draw: 6.2-19.4 µg/dL Source: Labcorp test 004051 |
| Prolactin Serum prolactin | Draw before a dose. Prolactin rose up to 180% after a single IV dose, at doses lower than those needed for the full GH effect (PMID 8954038). | Depends on age and sex. Labcorp adults 31-50: men 3.9-22.7, women 4.8-33.4 ng/mL Source: Labcorp test 004465 |
2. Mid-cycle (week 4)
draw before your morning dose; levels are expected to stay in range
| Marker | Why test it |
|---|---|
| IGF-1 Insulin-like growth factor 1 | Compare with baseline, same lab. No rise is expected. |
| Cortisol Serum cortisol, morning | Morning, before that day's dose. Basal cortisol is expected to stay in range. |
| Prolactin Serum prolactin | Before a dose. Basal prolactin is expected to stay in range. |
3. Post-cycle (2-4 weeks after your last dose)
| Marker | Why test it |
|---|---|
| IGF-1 Insulin-like growth factor 1 | Compare with baseline and week 4. |
| Fasting glucose Fasting plasma glucose | Confirms glucose is where it started. |
| Cortisol Serum cortisol, morning | Morning draw. Confirms the adrenal axis is back to baseline. |
| Prolactin Serum prolactin | Confirms prolactin is back to baseline. |
Ranges differ between labs. Cortisol ranges assume a morning draw, and prolactin and IGF-1 depend on age and sex, so read each result against the range printed on your own report and use the same lab each time. Glucose and HbA1c cut-offs are the American Diabetes Association's diagnostic thresholds; CBC ranges come from Cleveland Clinic.
What to expect
-
Cortisol and prolactin: brief rise after each dose; pre-dose levels should stay in range (baseline, week 4, post-cycle)
Right after a dose, both rise: cortisol about 24% and ACTH about 2-fold at 2 µg/kg IV (PMID 9253314); prolactin up to 180% (PMID 8954038). But in adults on 1.5 µg/kg twice daily under the skin for 16 weeks, there was no significant change in basal cortisol, urinary free cortisol or the prolactin response. The authors concluded that "over-stimulation of the pituitary adrenal axis and prolactin secretion do not occur" (PMID 10341859). The commonly reported community dose of 100-200 mcg 2-3 times a day is in the same range.
If it doesn't: A pre-dose cortisol or prolactin above range isn't what the research predicts. Stop and see a clinician. A draw taken within an hour or two after a dose may just be catching the spike, so time your draws before the dose.
-
IGF-1: no established rise (baseline, week 4, post-cycle)
Over 16 weeks of twice-daily hexarelin, IGF-1 did not change significantly, and the GH response shrank: down 31% at week 1, 36% at week 4 and 45% at week 16. It recovered fully 4 weeks after stopping (PMID 9589671). Two or three daily injections also left IGF-1 unchanged in young men (PMID 11888836).
If it doesn't: IGF-1 can't vouch for your vial. A flat result matches the research, and a rise doesn't prove it's hexarelin. Check the certificate of analysis for your batch.
-
Fasting glucose: may drift up; should stay in range (baseline, week 4, post-cycle)
Growth hormone raises blood sugar by working against insulin (PMID 29025199). No hexarelin trial has reported glucose or HbA1c, so this is class evidence, not hexarelin data.
If it doesn't: A move from normal into the prediabetes range (100 or higher) is a reason to stop and talk to a clinician, whatever the source of the vial.
Your labs can't check your vial
Your labs can't check your vial, and with no expected IGF-1 rise, IGF-1 can't even hint. No peer-reviewed study has tested grey-market hexarelin for identity or purity. FDA has not named hexarelin in its compounding safety review. Identity and purity get checked on the product's certificate of analysis, against the testing lab's own record.
What the research doesn't show
- The hormone data comes from small studies, mostly single IV doses (PMID 9253314, PMID 8954038, PMID 9437229). The only long-term data is one 16-week program of twice-daily injections (PMID 9589671, PMID 10341859).
- No hexarelin trial has reported glucose or HbA1c. They are on the panel as a GH-class precaution.
- Hexarelin's heart effects, through the CD36 receptor, have only been studied in animals (PMID 11988484).
- Banned in sport: the 2026 WADA Prohibited List names examorelin (hexarelin) as a GH-releasing peptide under S2, prohibited at all times.
Sources
- Ghigo E, et al. Adrenocorticotropin- and cortisol-releasing effect of hexarelin, a synthetic growth hormone-releasing peptide, in normal subjects and patients with Cushing's syndrome. J Clin Endocrinol Metab 1997. PMID 9253314
- Massoud AF, et al. Hexarelin-induced growth hormone, cortisol, and prolactin release: a dose-response study. J Clin Endocrinol Metab 1996. PMID 8954038
- Arvat E, et al. The GH, prolactin, ACTH and cortisol responses to hexarelin, a synthetic hexapeptide, undergo different age-related variations. Eur J Endocrinol 1997. PMID 9437229
- Rahim A, et al. Growth hormone status during long-term hexarelin therapy. J Clin Endocrinol Metab 1998. PMID 9589671
- Rahim A, et al. The effect of chronic hexarelin administration on the pituitary-adrenal axis and prolactin. Clin Endocrinol (Oxf) 1999. PMID 10341859
- Maccario M, et al. Impact of two or three daily subcutaneous injections of hexarelin, a synthetic growth hormone (GH) secretagogue, on 24-h GH, prolactin, adrenocorticotropin and cortisol secretion in humans. Eur J Endocrinol 2002. PMID 11888836
- Bodart V, et al. CD36 mediates the cardiovascular action of growth hormone-releasing peptides in the heart. Circ Res 2002. PMID 11988484
- Labcorp test 004051: Cortisol (AM reference range)
- Labcorp test 004465: Prolactin (reference ranges by age and sex)
- Kim SH, Park MJ. Effects of growth hormone on glucose metabolism and insulin resistance in human. Ann Pediatr Endocrinol Metab 2017. PMID 29025199
- Labcorp test 010363: Insulin-like growth factor 1 (IGF-1), age- and sex-specific reference ranges
- American Diabetes Association: Diagnosis (A1C and fasting plasma glucose thresholds)
- Cleveland Clinic: Complete blood count (normal values for adults)
- FDA: Certain bulk drug substances for use in compounding that may present significant safety risks (hexarelin not named)
- German Sport University Cologne (WADA-accredited lab): S2 Peptide hormones, growth factors, related substances and mimetics (2026 Prohibited List)
Educational content, not medical advice. Reference ranges differ by lab, so read your results against the range printed on your own report, and have a clinician review anything out of range.